Thoracoscopic Implantation of Epicardial Left Ventricular Lead for Cardiac Resynchronization Therapy

Hye Ree Kim

Samsung Medical Center

Kyunghee Lim

Dong-A University

Seung-Jung Park (✉ orthovics@gmail.com)

Samsung Medical Center

Jong-Sung Park

Dong-A University

Ji-Hoon Choi

Samsung Medical Center

Hee-Jin Kwon

Samsung Medical Center

Ju Youn Kim

Samsung Medical Center

Suryeun Chung

Samsung Medical Center

Dong-Seop Jung

Samsung Medical Center

Kyoung-Min Park

Samsung Medical Center

Young Keun On

Samsung Medical Center

June Soo Kim

Samsung Medical Center

Research Article

Keywords: Epicardia, Thoracoscopy, Cardiac resynchronization therapy, Heart failure

Posted Date: January 27th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1254575/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Purpose Limited data exist on the safety and efficacy of epicardial left ventricular(LV) lead placement using video-assisted thoracoscopic surgery(VATS) for cardiac resynchronization therapy(CRT).

Methods Acute and long-term outcomes of CRT were compared between patients with epicardial LV leads(Epicardial-LV group, n=13) and those with endocardial LV leads(Endocardial-LV group, n=243).

Results Epicardial LV leads were implanted by VATS alone(n=8) or along with mini-thoracotomy(n=5) for failed endocardial implantation(n=11) or recurrent lead dislodgement(n=2). All epicardial procedures under general anesthesia with one-lung ventilation were successfully completed in 2.3 ± 0.6 hours without phrenic nerve stimulation. LV pacing thresholds in the Epicardial-LV($1.5 \pm 1.0V$) and Endocardial-LV($1.3 \pm 0.8V$) were comparable($P=0.651$). All patients were discharged alive post-VATS 8.8 ± 3.9 days.

During the follow-up(34.3 ± 28.6 months), all patients with epicardial LV leads stayed alive except for one cardiac death post-CRT 14 months and one heart transplantation post-CRT 30 months. All epicardial LV leads maintained stable performance without dislodgement/significant changes in pacing threshold/impedance. LV lead dislodgement occurred only in endocardial-LV(7/243, 2.9%). Efficacy in both groups was comparable in terms of QRS narrowing, increase in LV ejection fraction, and survival free of cardiac death, or heart failure-related hospitalization.

Conclusion Epicardial LV lead placement using VATS can be a safe and effective alternative to endocardial implantation, with comparable long-term outcomes achieved by both approaches.

Introduction

Cardiac resynchronization therapy (CRT) in the forms of biventricular stimulation decreases mortality and morbidity in selected patients with symptomatic heart failure (HF) characterized by interventricular conduction delay¹⁻⁵. Conventional CRT recipients receive transvenous leads into their right atrium (RA), right ventricle (RV), and cardiac veins on the left ventricular (LV) free wall. Despite recent technological advancements in endocardial LV leads and delivery tools, the failure rate of LV lead implantation is still high (5-10%) for various reasons, including unsuitable cardiac vein anatomy, high pacing threshold, or phrenic nerve stimulation (PNS)^{6,7}. For these clinical situations, epicardial LV lead placement can be an alternative or rescue option⁸⁻¹⁰.

In our center, a minimally invasive video-assisted thoracoscopic surgery (VATS) began to be actively utilized since March 2010 for epicardial ablation of atrial fibrillation or implantation of LV leads, avoiding more invasive median sternotomy or full thoracotomy^{8,11,12}. In the present study, we sought to evaluate the short- and long-term safety and effectiveness of epicardial LV lead implantation using VATS. In addition, we compared overall CRT outcomes with epicardial LV leads to those with conventional endocardial LV leads.

Methods

Patient population

From October 2005, we prospectively entered information into our registry of cardiac implantable electronic devices on demographic, clinical, and device-related parameters in conjunction with electrocardiographic and echocardiographic data for all patients undergoing CRT implantation at our institution. In the registry, we carefully searched for consecutive patients with epicardial LV lead placement (Epicardial group). As a control group, data on consecutive patients who received successful transvenous LV lead placement during the same study period were also obtained (Endocardial group). Exclusion criteria were (1) replacement of CRT device, (2) epicardial LV implantation during open chest surgery, (3) in-hospital death, and (4) loss to follow-up after CRT implantation (Figure 1). All patients in the both groups had New York Heart Association (NYHA)

functional class II–IV HF symptoms refractory to optimal medical therapy (at least for 3 months), severe LV systolic dysfunction defined as LV ejection fraction (LVEF) $\leq 35\%$, and dyssynchrony suggested by wide QRS complexes (> 120 msec). This study complied with the Declaration of Helsinki, and Samsung medical center institutional review board (IRB) approved the study protocol and waived the need for consent from patients or relatives (IRB No. 2020-09-014).

Epicardial LV lead implantation for CRT

Epicardial LV lead implantation using VATS was performed as a second stage procedure after RV and RA leads were implanted in the electrophysiology laboratory. Under general anesthesia using a double endoluminal intubation for selective lung ventilation, patients were placed in the right lateral decubitus position with left chest elevated 30–40°. The left subclavian generator pocket created during the previous endocardial approach was reopened before one-lung ventilation. A 2-cm incision for a 15-mm port was made in the sixth left intercostal space at the posterior axillary line. A 30° thoracoscope was inserted for inspection of the left thoracic cavity. Two additional 5-mm ports were positioned in the fourth left intercostal space anterior to the anterior axillary line for the second port and mid-axillary level for the third port (Figure 2a). In cases of pleural adhesion, a 3 to 4 cm long left mini-thoracotomy was performed through the fourth intercostal space between the anterior and mid-axillary line. A 2-cm pericardiotomy was performed anterior to the phrenic nerve to expose the LV lateral wall. A screw-in unipolar pacing lead (Medtronic Model 5071 Pacing lead, Minneapolis, MN USA) was implanted via the 15-mm port into the LV lateral wall around obtuse marginal coronary artery. After threshold measurements, the proximal end of the LV lead was tunneled up to the subclavian pocket and connected to the generator along with the previously implanted RV and RA leads. A chest tube was inserted through the mid-axillary lesion. After completion of the operation, the location of the epicardial LV lead was confirmed by chest X-ray (Figure 2b).

Short-term and long-term outcomes

To assess in-hospital outcomes in the Epicardial group, we evaluated success rate of implantation, immediate QRS narrowing, any change in NYHA functional class, post-implant duration of care at intensive care unit (ICU), length of post-implant hospital stay, mortality, and procedure-related complications (LV lead dislodgement, the presence of PNS, hemothorax, or lead/device infection).

After discharge, clinical follow-ups with CRT-device interrogations were performed approximately 2 weeks after surgery and then every 3 months or when clinically indicated at our dedicated device clinic. Chest X-ray, 12-lead electrocardiograms, and biventricular pacing percentage (BiV-p%) reports were obtained at each clinic visit. The BiV-p% was calculated by averaging the values obtained at 3 months, 12-month, and the last visits after the procedures. During the follow-up period, adjustments to CRT pacing parameters such as pacing rate, mode, and atrioventricular/ventriculoventricular delay were left to the physician's discretion.

Long-term efficacy and safety of epicardial LV leads was evaluated and compared with those of endocardial LV leads in terms of changes in pacing threshold and impedance. Delayed-onset lead-related complications were also carefully reviewed. Clinical responses to CRT such as LV reverse remodeling, overall and cardiac mortality, and HF-related hospitalization (HF hospitalization) were compared between the Epicardial and Endocardial groups. Pre- and post-operative assessment of LVEF, LV end diastolic volume (EDV), and LV end systolic volume (ESV) were obtained using commercially available equipment (Vivid 9 or 7 from GE Healthcare, Chicago, IL, USA; Sonos 5500 from Philips, Andover, MA, USA). All death cases were defined as cardiac origin unless a definite non-cardiac cause could be identified. HF hospitalization was confirmed according to the 2016 European Society of Cardiology guidelines following careful assessment of HF symptoms or signs, chest radiography, echocardiography, and biomarkers.

Statistical analysis

Baseline data are presented as frequencies or the mean $\pm$ standard deviation (SD). Categorical variables were compared using χ^2 tests. Comparisons of continuous variables in the same patients was performed using Wilcoxon signed-rank test or paired t-test when appropriate. Continuous variables between the Epicardial and Endocardial groups were compared using the

Mann-Whitney test. Relative change in QRS duration (QRSd), LV volumes, and LV lead pacing variables were calculated as the differences between the last follow-up values and the baseline values divided by the baseline values. The probability of freedom from events was calculated according to the Kaplan-Meier method. A *P*-value <0.05 was considered to indicate statistical significance. All statistical analyses were performed using SPSS version 25.0 (SPSS, Chicago, IL).

Results

Baseline characteristics

From December 2011 to September 2020, we identified 13 consecutive patients who underwent VATS epicardial LV lead implantation after failure of the percutaneous approach due to the absence of suitable lateral cardiac vein (*n* = 5), tortuous coronary sinus and/or target branches (*n* = 3), anomalous cardiac veins (*n* = 3), or recurrent dislodgement of previous LV lead (*n* = 2). The mean ($\pm$ SD) age of the 13 patients was 61.9 ± 8.9 years, and male patients accounted for 46% (Table 1). An NYHA class III–IV HF symptom was observed in 62% (8/13) of patients. Baseline LVEF and QRSd were $26.4 \pm 4.6\%$ and 190 ± 31 ms, respectively. About one third of patients (31%, 4/13) had ischemic cardiomyopathy as their HF etiology. Previously, 6 patients had undergone sternotomy, including coronary artery bypass grafting (CABG) surgery (*n* = 2), valve replacement (*n* = 2), CABG with valve replacement (*n* = 1), and closure of ventricular septal defect (*n* = 1).

Table 1
Detailed Information on Patients with Epicardial Left Ventricular Lead

No.	Age (years)	Sex	Etiology of heart failure	NYHA	QRSd (ms)	QRS morphology	LVEF (%)	Previous Surgery	History of cardiac surgery	Surgical technique
1	49	F	Non-ICMP	III	224	LBBB	17.7		Absence of suitable lateral cardiac vein branches	Thoracoscopy
2	45	M	Non-ICMP	III	184	LBBB	24.7		Absence of suitable lateral cardiac vein branches	Thoracoscopy
3	62	M	Non-ICMP	III	214	LBBB	23.0	AVR	Tortuous target branches	Thoracoscopy
4	62	M	ICMP	II	168	LBBB	26.3	CABG, MVR	Absence of suitable lateral cardiac vein branches	Thoracoscopy
5	70	F	Non-ICMP	II	208	LBBB	23.3		Recurrent LV lead dislodgement & PNS	Thoracoscopy
6	73	M	ICMP	III	182	LBBB	24.3	CABG	Recurrent LV lead dislodgement & PNS	Thoracoscopy with mini-thoracotomy
7	64	M	Non-ICMP	IV	194	LBBB	23.4	MVR	Anomalous cardiac veins	Thoracoscopy
8	53	M	Non-ICMP	III	214	RBBB	25.0		Tortuous coronary sinus and target branches	Thoracoscopy with mini-thoracotomy
9	70	F	Non-ICMP	III	250	LBBB	30.0		Absence of suitable lateral cardiac vein branches	Thoracoscopy with mini-thoracotomy
10	61	F	Non-ICMP	III	166	LBBB	32.0		Absence of suitable lateral cardiac vein branches	Thoracoscopy

AVR, aortic valve replacement; CABG, coronary artery bypass graft; ICMP, ischemic cardiomyopathy; LV, left ventricle; LVEF, left ventricular ejection fraction; MVR, mitral valve replacement; NYHA, New York Heart Association functional classification; QRSd, QRS duration; VSD, ventricular septal defect; LBBB, left bundle branch block; RBBB, right bundle branch block; PNS, phrenic nerve stimulation.

No.	Age (years)	Sex	Etiology of heart failure	NYHA	QRSd (ms)	QRS morphology	LVEF (%)	Previous Surgery	History of cardiac surgery	Surgical technique
11	62	M	ICMP	II	145	LBBB	30.1	CABG	Coronary sinus atresia with unroofed coronary sinus	Thoracoscopy with mini-thoracotomy
12	74	F	Non-ICMP	II	168	LBBB	28.4		Tortuous coronary sinus and target branches	Thoracoscopy
13	59	F	Non-ICMP	II	151	LBBB	35.0	VSD closure	Anomalous cardiac veins	Thoracoscopy with mini-thoracotomy
AVR, aortic valve replacement; CABG, coronary artery bypass graft; ICMP, ischemic cardiomyopathy; LV, left ventricle; LVEF, left ventricular ejection fraction; MVR, mitral valve replacement; NYHA, New York Heart Association functional classification; QRSd, QRS duration; VSD, ventricular septal defect; LBBB, left bundle branch block; RBBB, right bundle branch block; PNS, phrenic nerve stimulation.										

During the same period, 243 consecutive patients in the Endocardial group with de novo CRT implantation were found in our CRT registry. There was no significant difference between the two groups in terms of baseline demographics, electro- and echocardiographic variables, CRT device-related factors, and discharge medications except for a wider pre-CRT QRSd (190 ± 31 vs. 170 ± 36 ms, $P = 0.019$) and more frequent previous cardiac surgery (38.5% vs. 17.3%, $P = 0.055$) in the Epicardial group (Table 2).

Table 2
Baseline Characteristics

	Epicardial LV lead (n = 13)	Endocardial LV lead (n = 243)	P Value
Age, years	61.9 ± 8.9	66.2 ± 12.7	0.225
Male gender	6 (46.2%)	152 (62.6%)	0.236
BMI (kg/m ²)	24.2 ± 2.9	23.3 ± 3.7	0.318
Hypertension	6 (46.2%)	134 (55.1%)	0.526
Diabetes	4 (30.8%)	89 (36.6%)	0.669
Chronic kidney disease	1 (7.7%)	33 (13.6%)	0.542
Stroke	3 (23.1%)	23 (9.5%)	0.113
Previous PCI	1 (7.7%)	47 (19.4%)	0.294
Previous cardiac surgery	5 (38.5%)	42 (17.3%)	0.055
Ischemic cardiomyopathy	4 (30.8%)	65 (26.7%)	0.750
LBBB	12 (92.3%)	210 (86.4%)	0.542
QRS duration, msec	190 ± 31	170 ± 36	0.019
LVEF, %	26.4 ± 4.6	25.6 ± 6.2	0.701
LVEDV, ml	230 ± 46	233 ± 77	0.848
LVESV, ml	181 ± 55	175 ± 66	0.615
CRT-defibrillator	12 (92.3%)	233 (95.9%)	0.538
Lateral LV pacing site	13 (100%)	227 (93.4%)	0.339
Non-apical LV pacing sites	13 (100%)	242 (99.6%)	0.817
LV pacing threshold, V	1.5 ± 1.0	1.3 ± 0.8	0.651
LV pacing pulse width, ms	0.5 ± 0.1	0.5 ± 0.1	0.538
LV lead impedance, Ω	354 ± 51	673 ± 267	<0.001
Discharge medications			
Beta-blocker	9 (69.2%)	181 (74.5%)	0.673
ARB/ACEi	11 (84.6%)	20 (8.4%)	0.980
Spironolactone	9 (69.2%)	178 (73.3%)	0.750
Values are expressed as n (%) or mean ± SD			
LV, left ventricle; BMI, body mass index; PCI, percutaneous coronary artery intervention; ARB, angiotensin receptor blocker; ACEi, angiotensin converting enzyme inhibitor; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; CRT, cardiac resynchronization therapy.			

Acute outcomes after epicardial LV lead implantation for CRT

All epicardial implantations of LV leads were successfully completed via VATS alone ($n = 8$) or along with mini-thoracotomy ($n = 5$) without significant immediate post-procedural complications. Mini-thoracotomy was needed in 5 patients with pleural adhesions. Of the 5 patients, 3 had a previous cardiac surgery such as CABG or ventricular septal defect closure. General anesthesia with one-lung ventilation was well-tolerated by all patients. The mean ($\pm$ SD) operation time was 2.3 ± 0.6 hours. The immediate post-implant LV pacing threshold was 1.5 ± 1.0 V (at 0.5 ± 0.1 ms of pulse width), which was not significantly different from that of the Endocardial group (1.3 ± 0.8 V at 0.5 ± 0.1 ms, $P = 0.651$) (Table 2). All patients in the Epicardial group were successfully transferred to the general ward after short-term care in the ICU (18.5 ± 16.6 hours). Chest tubes were removed in 3.1 ± 1.6 days, and all patients were discharged after a post-CRT hospital stay of 8.8 ± 3.9 days with a significant symptom improvement (NYHA functional class, 3.2 ± 0.7 to 2.0 ± 0.6 , $P = 0.001$). There was no PNS, hemothorax, or lead dislodgement during the index hospitalization.

Long-term outcomes

Long-term performance of epicardial LV leads was evaluated and compared with that of endocardial LV leads (Table 3). The Epicardial group showed no significant change in the LV pacing threshold (1.5 ± 1.0 to 1.7 ± 0.7 , $P = 0.154$) and impedance (353 ± 51 to 349 ± 62 , $P = 0.859$) during the 34.3 ± 28.6 months of follow-up (Figure 3). In addition, the relative changes in LV pacing threshold and impedance in both groups were not significantly different from each other (Table 3). In the Endocardial group, late LV lead dislodgement was found in 7 (2.9%) of 243 patients. However, there were no late epicardial LV lead-related complications such as dislodgement, PNS, lead fracture, hemopericardium, or hemothorax during the long-term follow-up of 34.3 ± 28.6 months.

Table 3
A comparison of the Two Groups at Baseline and During the Follow-Up

	Epicardial LV lead (n = 13)			Endocardial LV lead (n = 243)			<i>P</i> Value*
	Baseline	Last follow-up	<i>P</i> Value†	Baseline	Last follow-up	<i>P</i> Value†	
<i>Follow-up</i>							
Follow-up duration, month	34.3 ± 28.6			37.1 ± 32.7			0.913
BiV pacing percentage, %	96 ± 7			94 ± 16			0.772
<i>LV lead performance</i>							
Threshold, V	1.5 ± 1.0	1.7 ± 0.7	0.154	1.3 ± 0.8	1.5 ± 1.0	< 0.001	0.365*
Pulse width, ms	0.5 ± 0.1	0.5 ± 0.2	0.168	0.5 ± 0.1	0.5 ± 0.1	0.433	0.500*
Impedance, Ω	354 ± 51	349 ± 62	0.859	673 ± 267	694 ± 309	0.231	0.483*
<i>Electrocardiographic outcomes</i>							
QRS duration, ms	190 ± 31	150 ± 31	< 0.001	170 ± 36	141 ± 22	< 0.001	0.602*
<i>Echocardiographic outcomes</i>							
LVEF, %	25.7 ± 3.9	37.7 ± 15.1	0.023	25.6 ± 6.2	38.1 ± 14.5	< 0.001	0.866*
LVEDV,ml	218 ± 44	192 ± 83	0.484	236 ± 76	192 ± 91	< 0.001	0.592*
LVESV,ml	174 ± 60	118 ± 60	0.036	177 ± 64	132 ± 82	< 0.001	0.768*
Values are expressed as n (%) or mean ± SD.							
*, comparison of the relative changes in variables [(baseline – last FU) / baseline x 100] between the Epicardial and Endocardial groups.							
†, comparison between the baseline and the last follow-up values.							
LV, left ventricle; CRT, cardiac resynchronization therapy; BiV, biventricular; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume.							

The efficacy of CRT with epicardial versus endocardial leads was also compared during the long-term follow-up. Patients in the two groups revealed a marked and comparable QRS narrowing. Additionally, a remarkable LV reverse remodeling was observed in terms of LVEF increase and LVESV reduction. The LVEF increased from 25.7 ± 3.9% to 37.7 ± 15.1% in the Epicardial LV group ($P = 0.023$) while from 25.6 ± 6.2% to 38.1 ± 14.5% in the Endocardial LV group ($P < 0.001$).

All patients in the Epicardial group stayed alive except for one patient who died post-CRT 14 months and one heart transplantation patient who died post-CRT 30 months. The survival rates free of all-cause death ($P = 0.544$), cardiac death including left ventricular assist device implant and heart transplantation ($P = 0.749$), and HF-hospitalization ($P = 0.700$) were comparable between the two groups (Figure 4).

Discussion

The present study showed that the VATS epicardial LV lead implantation was safe and effective in patients with previous implantation failure or late dislodgement of the endocardial LV lead. Moreover, CRT with epicardial versus endocardial LV

lead was comparable in overall long-term LV lead performance, QRS narrowing, echocardiographic reverse remodeling, and clinical outcomes.

The failure rate of endocardial LV lead implantation has been progressively decreasing because of the advent of more elaborately designed LV leads, better delivery equipment, and more skilled operators¹³. However, the endocardial approach can still be challenging due to difficulties with coronary sinus access and lack of suitable implant sites, including no suitable vessels, high threshold, PNS, and lead instability. In cases where endocardial LV lead implantation is not feasible, surgical placement of epicardial LV leads can be used. Several prospective randomized trials and retrospective studies have demonstrated that epicardial LV lead placement is not inferior to endocardial LV lead placement for echocardiographic and clinical outcomes with excellent long-term safety outcomes^{14–16}. However, most of the previous data were derived from patients treated by sternotomy or thoracotomy, which is more invasive treatment than thoracoscopic surgery^{9,10,17}. Although a small number of studies were carried out on thoracoscopic epicardial LV lead implantation, the efficacy of CRT using the VATS approach was not compared using endocardial LV leads; if ever compared, only for a short period (6-12 months)^{18,19}.

In contrast, our data revealed that the VATS epicardial LV lead implantation without sternotomy showed satisfactory and comparable long-term (34.3 ± 28.6 months) outcomes with regards to LV lead performance, electro-/echocardiographic improvement, and clinical prognosis of patients compared with those using a conventional endocardial approach. Our results are in line with data from Marini et al., who demonstrated no differences in death, cardiovascular hospitalizations, or device-related complications between the Epicardial (thoracoscopically implanted) and Endocardial groups during a median follow-up of 24 months¹⁹.

Appropriate LV lead placement into the optimal pacing site is important for correction of LV dyssynchrony, and leads to better clinical outcomes of CRT^{20–22}. Epicardial LV lead implantation through an open chest technique offers direct visual control and allows an easier approach to the optimal pacing site overcoming unfavorable cardiac vein anatomy. However, the open chest approach is associated with more postoperative pain, larger surgical scar, and longer hospital stay for recovery. Accordingly, VATS epicardial LV lead implantation can be a better option than full sternotomy or standard thoracotomy.

There are several concerns for implantation of epicardial LV leads using VATS. First, many physicians may be reluctant to refer patients for this surgical treatment because general anesthesia with one-lung ventilation itself can aggravate patients with severe LV systolic dysfunction. Second, extensive experience of operators is required for this thoracoscopic technique. Finally, if the VATS approach fails, total operation time may be more prolonged with median sternotomy or left thoracotomy eventually required. However, general anesthesia with one-lung ventilation was well-tolerated by all of our patients with severe LV systolic dysfunction (range of LVEF, 18 to 35%). Additionally, all LV leads were successfully implanted into the lateral walls of the LV, one of the most optimal sites for CRT. Unsuitable areas with PNS, epicardial fat, or fibrosis were more easily identified and avoided during the VATS procedures, achieving comparable LV pacing thresholds to those in the Endocardial group. No significant in-hospital and long-term complications were observed in the Epicardial group. In previous studies as well, VATS approach was associated with reduced surgical-related complications^{10,19,23,24}. In terms of lead dislodgement, epicardial implant can have a definite advantage over the endocardial approach. Indeed, late LV lead dislodgement occurred only in the Endocardial group. Therefore, epicardial LV lead implantation using VATS can be effectively and safely used as a rescue method for patients with recurrent LV lead dislodgement, or even as a de novo way for those with unfavorable cardiac vein anatomy or when better targeted LV pacing is required.

Limitations

One of our major limitations of this study is the retrospective observational design of the analysis. Additionally, small numbers of patients in the single center in epicardial LV lead group may produce bias, thus prospective randomized studies on a larger scale are needed to validate the efficacy and safety of the LV lead implant using VATS for CRT more definitely.

Conclusion

Where suitably trained thoracoscopic surgeons are available, epicardial LV lead implantation using VATS can be an effective and safe alternative to the standard transvenous approach in CRT patients with difficult vein anatomy or endocardial lead dislodgement. The VATS epicardial LV leads implantation showed a stable long-term performance, offering comparable CRT outcomes compared to those treated by endocardial LV leads.

Declarations

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

1. Bradley, D. J. *et al.* Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. *JAMA* **289**, 730–740. <http://doi.org/10.1001/jama.289.6.730> (2003).
2. Bristow, M. R. *et al.* Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* **350**, 2140–2150. <http://doi.org/10.1056/NEJMoa032423> (2004).
3. Cleland, J. G. *et al.* The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* **352**, 1539–1549. <http://doi.org/10.1056/NEJMoa050496> (2005).
4. Curtis, A. B. *et al.* Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med* **368**, 1585–1593. <http://doi.org/10.1056/NEJMoa1210356> (2013).
5. Tang, A. S. *et al.* Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* **363**, 2385–2395. <http://doi.org/10.1056/NEJMoa1009540> (2010).
6. McAlister, F. A. *et al.* Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. *JAMA* **297**, 2502–2514. <http://doi.org/10.1001/jama.297.22.2502> (2007).
7. Ahsan, S. Y. *et al.* An 8-year single-centre experience of cardiac resynchronisation therapy: procedural success, early and late complications, and left ventricular lead performance. *Europace* **15**, 711–717. <http://doi.org/10.1093/europace/eus401> (2013).
8. Jeong, D. S. *et al.* Thoracoscopic left ventricular lead implantation in cardiac resynchronization therapy. *J Korean Med Sci* **27**, 1595–1597. <http://doi.org/10.3346/jkms.2012.27.12.1595> (2012).
9. Buiten, M. S., van der Heijden, A. C., Klautz, R. J. M., Schaliij, M. J. & van Erven, L. Epicardial leads in adult cardiac resynchronization therapy recipients: a study on lead performance, durability, and safety. *Heart Rhythm* **12**, 533–539. <http://doi.org/10.1016/j.hrthm.2014.11.004> (2015).
10. Jutley, R. S. *et al.* Video-assisted thoracoscopic implantation of the left ventricular pacing lead for cardiac resynchronization therapy. *Pacing and clinical electrophysiology: PACE* **31**, 812–818. <http://doi.org/10.1111/j.1540-8159.2008.01095.x> (2008).
11. On, Y. K. *et al.* Electrophysiologic Results After Thoracoscopic Ablation for Chronic Atrial Fibrillation. *Ann Thorac Surg* **100**, 1595-1602; discussion 1602-1593. <http://doi.org/10.1016/j.athoracsur.2015.04.127> (2015).
12. Lim, S. K., Kim, J. Y., On, Y. K. & Jeong, D. S. Mid-Term Results of Totally Thoracoscopic Ablation in Patients with Recurrent Atrial Fibrillation after Catheter Ablation. *Korean J Thorac Cardiovasc Surg* **53**, 270–276. <http://doi.org/10.5090/kjtcs.19.059> (2020).
13. Gamble, J. H. P. *et al.* Procedural Success of Left Ventricular Lead Placement for Cardiac Resynchronization Therapy: A Meta-Analysis. *JACC Clin Electrophysiol* **2**, 69–77. <http://doi.org/10.1016/j.jacep.2015.08.009> (2016).
14. van Dijk, V. F. *et al.* Effects of epicardial versus transvenous left ventricular lead placement on left ventricular function and cardiac perfusion in cardiac resynchronization therapy: A randomized clinical trial. *J Cardiovasc Electrophysiol* **28**,

917–923. <http://doi.org/10.1111/jce.13242> (2017).

15. Giraldi, F. *et al.* Long-term effectiveness of cardiac resynchronization therapy in heart failure patients with unfavorable cardiac veins anatomy comparison of surgical versus hemodynamic procedure. *J Am Coll Cardiol* **58**, 483–490. <http://doi.org/10.1016/j.jacc.2011.02.065> (2011).
16. Garikipati, N. V. *et al.* Comparison of endovascular versus epicardial lead placement for resynchronization therapy. *Am J Cardiol* **113**, 840–844. <http://doi.org/10.1016/j.amjcard.2013.11.040> (2014).
17. Rickard, J. *et al.* Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. *Heart Rhythm* **12**, 517–523. <http://doi.org/10.1016/j.hrthm.2014.11.013> (2015).
18. Shah, R. V., Lewis, E. F. & Givertz, M. M. Epicardial left ventricular lead placement for cardiac resynchronization therapy following failed coronary sinus approach. *Congest Heart Fail* **12**, 312–316. <http://doi.org/10.1111/j.1527-5299.2006.05568.x> (2006).
19. Marini, M. *et al.* Epicardial left ventricular lead implantation in cardiac resynchronization therapy patients via a video-assisted thoracoscopic technique: Long-term outcome. *Clin Cardiol* **43**, 284–290. <http://doi.org/10.1002/clc.23300> (2020).
20. Dekker, A. L. *et al.* Epicardial left ventricular lead placement for cardiac resynchronization therapy: optimal pace site selection with pressure-volume loops. *J Thorac Cardiovasc Surg* **127**, 1641–1647. <http://doi.org/10.1016/j.jtcvs.2003.10.052> (2004).
21. Singh, J. P. *et al.* Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. *Circulation* **123**, 1159–1166. <http://doi.org/10.1161/CIRCULATIONAHA.110.000646> (2011).
22. Butter, C. *et al.* Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. *Circulation* **104**, 3026–3029. <http://doi.org/10.1161/hc5001.102229> (2001).
23. Nelson, K. E., Bates, M. G., Turley, A. J., Linker, N. J. & Owens, W. A. Video-assisted thoracoscopic left ventricular pacing in patients with and without previous sternotomy. *Ann Thorac Surg* **95**, 907–913. <http://doi.org/10.1016/j.athoracsur.2012.11.022> (2013).
24. Navia, J. L. *et al.* Minimally invasive left ventricular epicardial lead placement: surgical techniques for heart failure resynchronization therapy. *Ann Thorac Surg* **79**, 1536-1544; discussion 1536-1544. <http://doi.org/10.1016/j.athoracsur.2004.10.041> (2005).

Figures

Figure 1

Flow diagram of patient enrollment

CRT-P/D, cardiac resynchronization therapy-pacemaker/defibrillator; *LV*, left ventricle

Figure 2

Serial changes in pacing threshold (a) and impedance (b) of epicardial and endocardia LV leads during the follow-up.

LV, left ventricle

Figure 3

Serial changes in pacing threshold (a) and impedance (b) of epicardial and endocardia LV leads during the follow-up.

LV, left ventricle

Figure 4

Kaplan-Meier survival curves of time to all cause death (a), to cardiac death (b), and to HF hospitalization (c) in the Endocardial and Epicardial groups.

HF, heart failure; *LV*, left ventricle